Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds aslo inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Abstract: Disclosed are compounds which bind VAL-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Abstract: Disclosed are a series of heteroaryl-&bgr;-alanine derivatives, compositions containing them, processes for their preparation and their use in medicine.

Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Abstract: Disclosed are a series of phenylalanine derivatives, to compositions containing them, to processes for their preparation, and to their use in medicine.

Abstract: Disclosed are certain alpha amino acid compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Abstract: Disclosed are certain 3-(heteroaryl)alanine derivatives which bind VLA-4 and inhibit leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Abstract: The compounds of this invention having Angiotensin II receptor binding properties and thus useful in the treatment of hypertension are of the formula: ##STR1## wherein: X.sup.1 =H, lower alkyl, phenyl or naphthyl;X.sup.2 is X.sup.1, perfluoroalkyl or halogen;X.sup.1 and X.sup.2 together are --(CH.sub.2).sub.n --where n is 3-6;X.sup.3 =H, lower alkyl, perfluoroalkyl, perchloroalkyl or halogen;X.sup.4 =5-tetrazolyl, carboxy or cyano;X.sup.5 =H, lower alkoxy or halogen;and the pharmaceutically acceptable salts thereof.

Abstract: Cyclic hexapeptides of the formula: ##STR1## in which X.sub.1 is Thr, Val or Abu;X.sub.2 is Phe, Trp or Tyr;n is one of the integers 2, 3 or 4;m is one of the integers 1, 2, 3 or 4;R.sub.1 is hydrogen or a hydroxyl protecting group for Thr;R.sub.2 is hydrogen or a hydroxyl protecting group for Tyr;R.sub.3 is hydrogen or a N.sup..epsilon. protecting group for Lys;R.sub.4 is hydrogen, alkanoyl, aroyl or an amino protecting group;or pharmaceutically acceptable salts thereof, are inhibitors of growth hormone secretion useful in the treatment of acromegaly and diabetes.

Abstract: The N-(1-carboxy-3-phenylpropyl)-dipeptides of the formula: ##STR1## inhibit angiotensin converting enzyme and serve as antihypertensive agents to reduce blood pressure in animals.

Abstract: Polypeptides of the formula: ##STR1## where X.sub.1 is either D- or L- Lys, Arg, His or Orn;X.sub.2 is either D- or L- Asn, His, Glu, Asp, Tyr, Trp or Phe;X.sub.3 is either D- or L- Trp;the linear precursor intermediates thereof and pharmaceutically acceptable salts and amides thereof are inhibitors of growth hormone release, active for periods of two hour and more. In addition, the compounds of this invention normalize post-prandial glucose and triglyceride levels in diabetics. The compounds are useful for treatment of patients suffering from diabetes mellitus and excessive growth hormone secretion (acromegaly).

Abstract: The nonapeptides ##STR1## in which X.sub.1 is either L- or D- His, Lys or Arg;X.sub.2 is either L- or D- Phe, Tyr, Trp, Leu, Met, His, Glu or Asp;X.sub.3 is Phe, Tyr, Trp, Leu or Met;X.sub.4 is L- or D-Trp;X.sub.5 is Thr, Val or Abu; and,X.sub.6 is either L- or D- Phe, Tyr, Trp, Leu, Met, Ser or Thr;the linear precursor intermediates and pharmaceutically acceptable salts and amides thereof are inhibitors of growth hormone release and are anti-secretory agents which act as H.sub.2 -receptor antagonists.

Abstract: Compounds which inhibit the brain enzyme degradation of enkephalins and which exhibit their own analgesic effect, having the formula ##STR1## wherein R.sub.1 is hydrogen or lower alkyl; X is hydrogen, hydroxy, halo, nitro, amino or lower alkoxy; R.sub.2 is hydrogen or ##STR2## wherein R.sub.3 is lower alkyl and R.sub.4 is L- or D-Thz or Pro, and the pharmaceutically acceptable salts thereof.

Abstract: The polypeptides, ##STR1## the linear precursor intermediates therefor or non-toxic acid addition salts thereof in whichX.sub.2 is NH.sub.2, Ala-Gly-, Ala-D-Ala-, Gly-Gly-Gly-, lower alkanoyl or benzoyl;X.sub.4 is Arg, His, D-Arg or D-His;X.sub.5 is His, Tyr, Glu, D-His, D-Tyr or D-Glu;X.sub.7 is Trp, Tyr, Met or His; andX.sub.8 is Trp or D-Trp;inhibit the release of growth hormone and are useful in the treatment of acromegaly and diabetes.

Abstract: Polypeptides of the formula: ##STR1## in which X.sub.1 is Phe, D-Phe or C.sub.6 H.sub.5 CH.sub.2 CH.sub.2 CO--;X.sub.2 is Phe, Tyr, Trp, Met or Leu;X.sub.3 is Trp or D-Trp;X.sub.4 is Thr, Val, .alpha.-Abu or Phe;andX.sub.5 is Phe, D-Phe or --NHCH.sub.2 CH.sub.2 C.sub.6 H.sub.3 ;the linear precursor intermediates thereof and pharmaceutically acceptable salts and amides thereof are selective inhibitors of growth hormone release without materially altering blood serum levels of glucagon or insulin. In addition, the above-described compounds are active growth hormone suppressants for periods as long as two hours.

Abstract: The analgesic tripeptide amides of the formula: ##STR1## in which X.sup.2 is D-Ala, D-Ser, D-Thr, D-Met, D-Cys, D-Trp, or D-Asn;R.sup.1 is hydrogen, alkyl of 1 to 6 carbon atoms, allyl, cyclopropylmethyl or cyclobutylmethyl;R.sup.2 is hydrogen or alkyl of 1 to 6 carbon atoms;R.sup.3 is hydrogen or alkyl of 1 to 6 carbon atoms;R.sup.4 is isobutyl, cyclohexyl, benzyl, p-halobenzyl or p-nitrobenzyl;R.sup.5 is hydrogen or alkyl of 1 to 6 carbon atoms; andR.sup.6 is hydrogen, alkyl of 1 to 6 carbon atoms, 2-hydroxyethyl, benzyl, diphenylmethyl, phenyl, p-halophenyl, p-nitrophenyl, ##STR2## or --CH.sub.2 CH.sub.2 SCH.sub.3 ; or a pharmaceutically acceptable salt thereof.